



(51) International Patent Classification:

G01N 33/569 (2006.01) A61P 31/14 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/SG2021/050196

(22) International Filing Date:

07 April 2021 (07.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202003207Y 07 April 2020 (07.04.2020) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **CHAN, Yi Hao**; c/o A*STAR Infectious Diseases Labs (A*STAR ID Labs), 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **FONG, Siew Wai**; c/o A*STAR Infectious Diseases Labs (A*STAR ID Labs), 8A Biomedical Grove, #04-06 Immunos, Singapore

138648 (SG). **RÖTZSCHKE, Olaf**; c/o Singapore Immunology Network (SIgN), 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **RÉNIA, Laurent Claude**; c/o A*STAR Infectious Diseases Labs (A*STAR ID Labs), 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **NG, Lisa Fong Poh**; c/o A*STAR Infectious Diseases Labs (A*STAR ID Labs), 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **LEE, Bennett**; c/o Singapore Immunology Network (SIgN), 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG).

(74) Agent: **DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: A METHOD OF ASSESSING A DISEASE STATE IN A SUBJECT INFECTED WITH CORONAVIRUS




FIG. 1A

(57) Abstract: There is provided a method of identifying a risk of severe disease in a subject infected with SARS-CoV-2, the method comprising: determining a level of one or more immune mediators, including interleukin-6 (IL-6), in the subject's sample; and identifying a risk of severe disease based on the level of the one or more immune mediators, wherein the risk of severe disease is positively associated with the level of the one or more immune mediators and wherein the one or more immune mediators comprises at least one of cytokines, chemokines, growth factors or combinations thereof. Also provided are related methods and products. In addition, a method of treating SARS-CoV-2 infection with an agent capable of reducing the level of IL-6, including tocilizumab and sarilumab, is claimed.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*